Matthew is an associate editor for The American Journal of Managed Care® (AJMC®). He joined AJMC® in 2019 and creates content for Medical World News®, a 24-hour online program developed MJH Life Sciences® focusing on pressing topics within managed care, as well as the nonwork-related activities of health care stakeholders.
He has a BA in journalism & media studies and economics from Rutgers University. You can connect with Matthew on LinkedIn.
ICYMI: Highlights From the 2022 American Academy of Dermatology Meeting
December 17th 2022This American Academy of Dermatology (AAD) Annual Meeting covered a breakthrough therapy for the management of vitiligo, clinical and epidemiological differences of certain dermatologic diseases, and the role of dietary triggers on patient outcomes.
ICYMI: Top Content From DDW 2022
December 16th 2022Several therapeutic innovations in the management of Clostridioides difficile infection recurrence, current evidence on the efficacy of weight loss procedures in reversing nonalcoholic fatty liver disease, and an interview the use of artificial intelligence were spotlighted at Digestive Disease Week (DDW) 2022.
Greater Risk of Cataract Surgery Shown in Patients With Atopic Dermatitis, Allergic Diseases
December 16th 2022Korean patients with allergic diseases, including atopic dermatitis (AD), allergic rhinitis (AR), and asthma, had a higher risk of cataract surgery, and the combination of AD and AR resulted in the highest risk.
Dr Liz Lightstone: Lupus Nephritis Misconceptions Contributing to Underdiagnosis, Low-Value Care
December 15th 2022Liz Lightstone, MBBS, PhD, FRCP, professor of Renal Medicine for the Faculty of Medicine, Imperial College London, discussed how sexism and other factors cause certain symptoms of lupus nephritis to be overlooked, contributing to delays in diagnosis and care.
Racial Disparities Shown for Delayed Diagnosis, Dermatologic Care in Hidradenitis Suppurativa
December 13th 2022Non-White patients with hidradenitis suppurativa reported longer delay in diagnosis than their White counterparts. In addition, Black patients did not receive dermatologic care as early in their disease course as other racial groups.
Improved Patient-Reported Outcomes Shown With Mediterranean Diet in Parkinson Disease
December 12th 2022Patients with Parkinson disease who adhered to Mediterranean (MEDI) and Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diets were associated with fewer patient-reported symptoms over time, in which the MIND diet showed greater reductions in symptom severity compared with MEDI.
DAA Therapy Linked With Improved Liver, Mortality Outcomes in Patients With Chronic Hepatitis C
December 12th 2022Use of direct-acting antiviral (DAA) treatment (without interferon) was shown to reduce liver and nonliver complications, as well as improve long-term overall survival among patients with chronic hepatitis C.
Childhood Maltreatment Associated With Atopic Disease
December 9th 2022Patients exposed to childhood maltreatment were at greater risk for developing atopic disease compared with unexposed counterparts, and risk of atopic dermatitis and allergic rhinoconjunctivitis may have been attentuated by misdiagnosis.
Lower Risk of Cardiovascular, Metabolic Outcomes Associated With Rituximab for Pemphigus Treatment
December 8th 2022Patients with pemphigus reported lower risk of myocardial infarction and stroke, among other cardiovascular and metabolic outcomes, when treated with rituximab compared with the first-line corticosteroid-sparing agents azathioprine and mycophenolate mofetil.
Assessing Frequency of Orthostatic Hypotension in Patients With Parkinson Disease
December 7th 2022Frequency of orthostatic hypotension among Ethiopian patients with Parkinson disease (PD) was shown to be higher than that among healthy controls, with a higher proportion of constipation, urinary urgency, and nocturia symptoms reported in those with PD.
COVID-19 Mortality Risk More Than Doubled Among Homeless Patients
December 6th 2022A cross-sectional study showed that patients experiencing homelessness were at more than 2-fold greater age-adjusted mortality risk due to COVID-19 compared with the general population, with these increased risks observed across race/ethnicity and sex status.
Glucose-Lowering Drugs May Reduce Risk of COVID-19–Related Adverse Events in Patients With Diabetes
December 6th 2022Patients with diabetes who reported use of sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, or metformin prior to COVID-19 infection were associated with lower COVID-19–related adverse outcomes during hospitalization.
Gaps Remain in HPV Vaccine Coverage for Children Due to COVID-19 Pandemic
December 3rd 2022The monthly volume of human papillomavirus (HPV) vaccine doses administered have returned to the level observed prior to the COVID-19 pandemic among children in an integrated health care system in California, but HPV vaccine coverage remains lower compared with prepandemic levels.
Dr Liz Lightstone on Race and Sociodemographic Implications in Lupus Nephritis
December 3rd 2022Liz Lightstone, MBBS, PhD, FRCP, professor of renal medicine for the Faculty of Medicine, Imperial College London, discussed the influence of genetics and background on the care management of lupus nephritis.
Low Diversity Shown Among Medical Students Pursuing Dermatology
December 2nd 2022Female allopathic medical students pursuing careers in dermatology were less likely than those pursuing other specialties to be from racial and ethnic groups underrepresented in medicine or be a sexual minority, with a lack of interest in underserved care and public health shown overall.
Use of PRO Measures Lacking in Acne Vulgaris and Rosacea Clinical Trials, Study Finds
December 2nd 2022Patient-reported outcome (PRO) measures were included in approximately one-half of acne vulgaris and rosacea randomized controlled trials, despite their utility in capturing the patient perspective.
FDA Approves First Fecal Transplant Therapy for Prevention of CDI Recurrence
December 1st 2022Ferring’s Rebyota, a novel first-in-class microbiota-based live biotherapeutic, has been approved by the FDA for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years and older, following antibiotic treatment for recurrent CDI.
Empagliflozin Has Similar Efficacy Across Subgroups, More Data Needed in CKD: Dr Jennifer Green
November 26th 2022Data on empagliflozin in chronic kidney disease (CKD) showed the drug had similar efficacy across subgroups, but more data is needed to really understand the benefit of the drug in CKD, said Jennifer Green, MD, professor of medicine at Duke University School of Medicine, member of Duke Clinical Research Institute, and EMPA-KIDNEY collaborator.
Long-term Pioglitazone Use May Reduce Risk of Parkinson Disease in Patients With Diabetes
November 25th 2022Findings of a meta-analysis show that pioglitazone use with a dose duration greater than 438 days was associated with a significantly reduced risk of Parkinson disease in patients with diabetes.
Dr Jason Ezra Hawkes on Advances in Clinical Research and Gaps in Knowledge for Atopic Dermatitis
November 24th 2022Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, spoke on how clinical studies in atopic dermatitis (AD) are increasingly investigating topics that remain unknown for disease management, including primary vs secondary failures and AD pathophysiology across different ethnic groups.